Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEYOND: Phase 3 study of BION-1301 in adults with IgA nephropathy
CTR20243367Phase 3Active
- Sponsor
- Chinook Therapeutics
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of zigakibart in IgA nephropathy (IgAN), sponsored by Chinook Therapeutics. Started Nov 2024; status: active.
02
Drugs
zigakibart
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20243367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243367.